Comprehensive Analysis of High-Sensitive Flow Cytometry and Molecular Mensurable Residual Disease in Philadelphia Chromosome-Positive Acute Leukemia
International Journal of Molecular Sciences · 27.02.2025 · 26 (5) · 2116
DOI: 10.3390/ijms26052116 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.02.2025. Verfasst von Ana Paula de Azambuja und 7 weiteren Autor:innen. Beteiligte Einrichtung: Hospital de Clínicas, Universidade Federal do Paraná, Curitiba 80060-900, Brazil. Hauptthemen laut MEDLINE: Neoplasm, Residual, Flow Cytometry, Philadelphia Chromosome, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PROGRAMA NACIONAL DE APOIO À ATENÇÃO ONCOLÓGICA (PRONON), Associação dos Amigos do Hospital de Clínicas (AAHC).
Abstract (Originalsprache)
Monitoring measurable residual disease (MRD) is critical for the management of B-cell acute lymphoblastic leukemia (B-ALL). While a quantitative assessment of BCR::ABL1 transcripts is standard for Philadelphia chromosome-positive cases (Ph+ ALL), a multiparameter flow cytometry (FCM) is commonly used for MRD detection in other genetic subtypes. A total of 106 B-ALL patients underwent genetic and phenotypic analyses. Among them, 27 patients (20 adults and 7 children) harbored the t(9;22)(q34.1;q11.2) translocation and/or the BCR::ABL1 rearrangement. A high correlation between the BCR::ABL1 transcript levels (PCR-MRD) and a standardized FCM-based method for MRD detection (FCM-MRD) was observed (r = 0.7801, p < 0.001), with a concordance rate of 88% (κ = 0.761). The FCM detected MRD in 82.9% of the samples with transcript levels of > 0.01%. The CD34+CD38−/dim blast pattern was significantly more frequent in Ph+ ALL (77.7%), compared to other B-ALL cases (20.2%, p < 0.0001). Additionally, Ph+ ALL exhibited a higher expression of CD66c+/CD73+ (94.0% vs. 56.9%), CD66c+/CD304+ (58.8% vs. 6.9%), and CD73+/CD304+ (75.5% vs. 15.5%) than the other B-ALL subtypes (p < 0.001). In conclusion, this high-sensitivity FCM-MRD demonstrated comparable performance to the PCR-MRD, serving as a complementary tool for MRD assessment in Ph+ ALL. Moreover, a distinct leukemia-associated immunophenotype was identified, highlighting potential biomarkers for MRD monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital de Clínicas, Universidade Federal do Paraná, Curitiba 80060-900, Brazil.
- Duke Children's Hospital, Durham, NC 27710, USA.
ORCID-Profile: Ana Paula de Azambuja, Miriam Perlingeiro Beltrame, Alexandra Cristina Senegaglia, Vaneuza Araujo Moreira Funke
Förderung
- PROGRAMA NACIONAL DE APOIO À ATENÇÃO ONCOLÓGICA (PRONON)
- Associação dos Amigos do Hospital de Clínicas (AAHC)
Zitieren
APA
de Azambuja, A. P., Mion, A. L. V., Schluga, Y. C., Beltrame, M. P., Senegaglia, A. C., Funke, V. A. M., Bonfim, C., & Pasquini, R. (2025). Comprehensive Analysis of High-Sensitive Flow Cytometry and Molecular Mensurable Residual Disease in Philadelphia Chromosome-Positive Acute Leukemia. International Journal of Molecular Sciences, 26(5), 2116. https://doi.org/10.3390/ijms26052116
Vancouver
de Azambuja AP, Mion ALV, Schluga YC, Beltrame MP, Senegaglia AC, Funke VAM, et al. Comprehensive Analysis of High-Sensitive Flow Cytometry and Molecular Mensurable Residual Disease in Philadelphia Chromosome-Positive Acute Leukemia. International Journal of Molecular Sciences. 2025;26(5):2116. doi:10.3390/ijms26052116
BibTeX
@article{deAzambuja2025,
author = {de Azambuja, Ana Paula and Mion, Ana Lucia Vieira and Schluga, Yara Carolina and Beltrame, Miriam Perlingeiro and Senegaglia, Alexandra Cristina and Funke, Vaneuza Araujo Moreira and Bonfim, Carmem and Pasquini, Ricardo},
title = {Comprehensive Analysis of High-Sensitive Flow Cytometry and Molecular Mensurable Residual Disease in Philadelphia Chromosome-Positive Acute Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {5},
pages = {2116},
doi = {10.3390/ijms26052116}
}
EUVIMED